You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNaratriptan
Accession NumberDB00952  (APRD00220)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Naratriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.

Structure
Thumb
Synonyms
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
Naratriptanum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amergetablet, film coated1 mg/1oralGlaxo Smith Kline Llc1998-02-26Not applicableUs
Amergetablet2.5 mgoralGlaxosmithkline Inc1998-05-05Not applicableCanada
Amergetablet1 mgoralGlaxosmithkline Inc1998-05-05Not applicableCanada
Amergetablet, film coated2.5 mg/1oralGlaxo Smith Kline Llc1998-02-26Not applicableUs
Sandoz Naratriptantablet2.5 mgoralSandoz Canada Incorporated2010-04-08Not applicableCanada
Teva-naratriptantablet2.5 mgoralTeva Canada Limited2009-12-01Not applicableCanada
Teva-naratriptantablet1 mgoralTeva Canada Limited2009-12-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-naratriptantablet1 mgoralApotex IncNot applicableNot applicableCanada
Apo-naratriptantablet2.5 mgoralApotex IncNot applicableNot applicableCanada
Naratriptantablet, film coated1 mg/1oralTeva Pharmaceuticals USA Inc2013-08-122015-11-30Us
Naratriptantablet1 mg/1oralRoxane Laboratories, Inc.2010-07-07Not applicableUs
Naratriptantablet, coated1 mg/1oralSandoz Inc2010-07-07Not applicableUs
Naratriptantablet, film coated2.5 mg/1oralSun Pharmaceutical Industries Limited2011-02-22Not applicableUs
Naratriptantablet, film coated2.5 mg/1oralOrchid Pharma Inc2012-12-12Not applicableUs
Naratriptantablet, film coated1 mg/1oralOrchid Pharma Inc2012-12-12Not applicableUs
Naratriptantablet, film coated2.5 mg/1oralMylan Pharmaceuticals Inc.2012-06-13Not applicableUs
Naratriptantablet2.5 mg/1oralHeritage Pharmaceuticals Inc.2011-03-15Not applicableUs
Naratriptantablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.2012-06-13Not applicableUs
Naratriptantablet1 mg/1oralHeritage Pharmaceuticals Inc.2011-03-15Not applicableUs
Naratriptantablet, film coated2.5 mg/1oralTeva Pharmaceuticals USA Inc2013-08-092015-10-31Us
Naratriptantablet2.5 mg/1oralRoxane Laboratories, Inc.2010-07-07Not applicableUs
Naratriptantablet, coated2.5 mg/1oralSandoz Inc2010-07-07Not applicableUs
Naratriptan Hydrochloridetablet, film coated2.5 mg/1oralPaddock Laboratories, LLC2010-07-08Not applicableUs
Naratriptan Hydrochloridetablet, film coated1 mg/1oralPaddock Laboratories, LLC2010-07-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NaramigNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Naratriptan hydrochloride
ThumbNot applicableDBSALT001246
Categories
UNIIQX3KXL1ZA2
CAS number121679-13-8
WeightAverage: 335.464
Monoisotopic: 335.166747749
Chemical FormulaC17H25N3O2S
InChI KeyInChIKey=AMKVXSZCKVJAGH-UHFFFAOYSA-N
InChI
InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
IUPAC Name
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamide
SMILES
CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndoles
Direct ParentIndoles
Alternative Parents
Substituents
  • Indole
  • Aralkylamine
  • Benzenoid
  • Substituted pyrrole
  • Piperidine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute treatment of migraine attacks with or without aura in adults.
PharmacodynamicsNaratriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonist. Naratriptan has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans.
Mechanism of actionThree distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Related Articles
AbsorptionWell absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
Volume of distribution
  • 170 L
Protein binding28%-31% (over the concentration range of 50 to 1000 ng/mL)
Metabolism

Primarily hepatic. In vitro, naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.

Route of eliminationNot Available
Half life5-8 hours
Clearance
  • 6.6 mL/min/kg
ToxicitySymptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment17361120
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9668
Caco-2 permeable-0.7657
P-glycoprotein substrateSubstrate0.6958
P-glycoprotein inhibitor INon-inhibitor0.6055
P-glycoprotein inhibitor IINon-inhibitor0.8139
Renal organic cation transporterNon-inhibitor0.5982
CYP450 2C9 substrateNon-substrate0.8257
CYP450 2D6 substrateNon-substrate0.5565
CYP450 3A4 substrateSubstrate0.6693
CYP450 1A2 substrateInhibitor0.5521
CYP450 2C9 inhibitorNon-inhibitor0.9034
CYP450 2D6 inhibitorNon-inhibitor0.6785
CYP450 2C19 inhibitorNon-inhibitor0.804
CYP450 3A4 inhibitorNon-inhibitor0.5914
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.6042
CarcinogenicityNon-carcinogens0.8226
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5630 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.608
hERG inhibition (predictor II)Inhibitor0.6772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Paddock laboratories inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg
Tabletoral2.5 mg
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral2.5 mg/1
Tabletoral1 mg/1
Tabletoral2.5 mg/1
Tablet, coatedoral1 mg/1
Tablet, coatedoral2.5 mg/1
Prices
Unit descriptionCostUnit
Amerge 9 2.5 mg tablet Box277.47USD box
Amerge 9 1 mg tablet Box275.67USD box
Amerge 1 mg tablet32.77USD tablet
Amerge 2.5 mg tablet32.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4997841 No1993-07-072010-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point246 °C (HCl salt)Not Available
water solubility35 mg/mLNot Available
logP1.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.114 mg/mLALOGPS
logP2.16ALOGPS
logP1.44ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)11.55ChemAxon
pKa (Strongest Basic)9.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area65.2 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.26 m3·mol-1ChemAxon
Polarizability38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sandip Vasant Chikhalikar, Maruti Ghagare, “Process for the synthesis of naratriptan.” U.S. Patent US20120220778, issued August 30, 2012.

US20120220778
General References
  1. Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [PubMed:12463278 ]
  2. Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [PubMed:16389295 ]
  3. Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [PubMed:15320857 ]
External Links
ATC CodesN02CC02
AHFS Codes
  • 28:32.28
PDB EntriesNot Available
FDA labelDownload (1.93 MB)
MSDSDownload (29.8 KB)
Interactions
Drug Interactions
Drug
AcepromazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Acetophenazine.
AmisulprideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.
AripiprazoleThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.
BenzquinamideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Benzquinamide.
CabergolineCabergoline may increase the vasoconstricting activities of Naratriptan.
CarphenazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorprothixene.
ClozapineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Clozapine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Naratriptan.
DroperidolThe risk or severity of adverse effects can be increased when Naratriptan is combined with Droperidol.
DroxidopaNaratriptan may increase the hypertensive activities of Droxidopa.
FencamfamineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fencamfamine.
FlupentixolThe risk or severity of adverse effects can be increased when Naratriptan is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Naratriptan.
GranisetronGranisetron may increase the serotonergic activities of Naratriptan.
HaloperidolThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.
LoxapineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Loxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Methotrimeprazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Metoclopramide.
MolindoneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Molindone.
OlanzapineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.
PerphenazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.
PimozideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Piperacetazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.
SertindoleThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sertindole.
SulpirideThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Naratriptan.
ThioridazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Naratriptan.
TrifluoperazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Naratriptan is combined with Triflupromazine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. [PubMed:10563228 ]
  2. Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA: The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology. 2002 Mar;42(3):374-85. [PubMed:11897116 ]
  3. Pauwels PJ, Colpaert FC: Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Eur J Pharmacol. 1996 Apr 4;300(1-2):141-5. [PubMed:8741180 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. [PubMed:12010764 ]
  6. Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [PubMed:14725972 ]
  7. Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [PubMed:14728705 ]
  8. Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000. [PubMed:20687618 ]
  9. Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. [PubMed:10410185 ]
  10. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
  11. Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [PubMed:12463278 ]
  12. Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [PubMed:16389295 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. [PubMed:12010764 ]
  2. Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [PubMed:14725972 ]
  3. Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [PubMed:14728705 ]
  4. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [PubMed:9650800 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000. [PubMed:20687618 ]
  7. Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. [PubMed:10410185 ]
  8. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
  9. Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [PubMed:12463278 ]
  10. Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [PubMed:16389295 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1F
Uniprot ID:
P30939
Molecular Weight:
41708.505 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [PubMed:14725972 ]
  3. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
  4. Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [PubMed:12463278 ]
  5. Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [PubMed:15320857 ]
  6. Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. [PubMed:14614913 ]
  7. Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [PubMed:12434581 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [PubMed:14728705 ]
  2. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Millson DS, Tepper SJ, Rapoport AM: Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404. [PubMed:11249525 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12